Alesha A Thai1, Benjamin J Solomon1,2. 1. Department of Medical Oncology, Peter MacCallum Cancer Centre. 2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Abstract
PURPOSE OF REVIEW: The review will highlight recent advances in development of ALK-TKIs and management of patients with ALK-positive nonsmall cell lung cancer. RECENT FINDINGS: There has been rapid progress in the use of targeted therapies for ALK-positive NSCLC. Since the discovery, development and approval of crizotinib in 2011, three second-generation ALK-TKIs, ceritinib, alectinib and brigatinib have been approved by the FDA. A range of newer generation ALK inhibitors with improved potency against ALK and against mutations that confer resistance to crizotinib are in clinical development. SUMMARY: Our review will discuss the recent phase III data with ceritinib and alectinib as well as clinical trials with other ALK inhibitors. We will also address two important issues in the management of ALK-positive NSCLC, prevention and treatment of brain metastases and management of emergent ALK-TKI resistance mechanisms.
PURPOSE OF REVIEW: The review will highlight recent advances in development of ALK-TKIs and management of patients with ALK-positive nonsmall cell lung cancer. RECENT FINDINGS: There has been rapid progress in the use of targeted therapies for ALK-positive NSCLC. Since the discovery, development and approval of crizotinib in 2011, three second-generation ALK-TKIs, ceritinib, alectinib and brigatinib have been approved by the FDA. A range of newer generation ALK inhibitors with improved potency against ALK and against mutations that confer resistance to crizotinib are in clinical development. SUMMARY: Our review will discuss the recent phase III data with ceritinib and alectinib as well as clinical trials with other ALK inhibitors. We will also address two important issues in the management of ALK-positive NSCLC, prevention and treatment of brain metastases and management of emergent ALK-TKI resistance mechanisms.
Authors: Mizuki Nishino; Tomoyuki Hida; Sasha Kravets; Suzanne E Dahlberg; Christine A Lydon; Hiroto Hatabu; Bruce E Johnson; Mark M Awad Journal: Eur J Radiol Open Date: 2020-01-28
Authors: Dianne Hartgerink; Britt van der Heijden; Dirk De Ruysscher; Alida Postma; Linda Ackermans; Ann Hoeben; Monique Anten; Philippe Lambin; Karin Terhaag; Arthur Jochems; Andre Dekker; Janna Schoenmaekers; Lizza Hendriks; Jaap Zindler Journal: Front Oncol Date: 2018-05-09 Impact factor: 6.244